Loxo Oncology, Inc. (NASDAQ:LOXO) insider Naarden Jacob Van sold 1,541 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $73.73, for a total transaction of $113,617.93. Following the sale, the insider now directly owns 1,541 shares in the company, valued at approximately $113,617.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Naarden Jacob Van also recently made the following trade(s):

  • On Tuesday, August 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $73.57, for a total transaction of $226,742.74.

Loxo Oncology, Inc. (LOXO) traded up 0.91% during mid-day trading on Wednesday, hitting $74.19. 381,596 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $74.65 and its 200-day moving average price is $55.69. Loxo Oncology, Inc. has a 12 month low of $17.14 and a 12 month high of $83.12. The stock’s market cap is $2.21 billion.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by $0.15. During the same period last year, the company earned ($0.77) EPS. Equities analysts expect that Loxo Oncology, Inc. will post ($4.34) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Loxo Oncology, Inc. (LOXO) Insider Naarden Jacob Van Sells 1,541 Shares” was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/16/loxo-oncology-inc-loxo-insider-naarden-jacob-van-sells-1541-shares.html.

A number of analysts have weighed in on the stock. BidaskClub cut shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. BTIG Research reaffirmed a “buy” rating and set a $75.00 target price on shares of Loxo Oncology in a research note on Thursday, August 3rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $94.00 target price (up previously from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. Zacks Investment Research cut shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Cowen and Company reaffirmed an “outperform” rating on shares of Loxo Oncology in a research note on Monday, June 5th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $79.67.

A number of large investors have recently made changes to their positions in LOXO. FMR LLC raised its stake in shares of Loxo Oncology by 12.1% in the second quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock worth $352,420,000 after buying an additional 472,814 shares during the period. Aisling Capital LLC raised its stake in shares of Loxo Oncology by 4.0% in the first quarter. Aisling Capital LLC now owns 4,188,920 shares of the biopharmaceutical company’s stock worth $176,270,000 after buying an additional 160,000 shares during the period. Wellington Management Group LLP raised its stake in shares of Loxo Oncology by 34.4% in the first quarter. Wellington Management Group LLP now owns 2,437,872 shares of the biopharmaceutical company’s stock worth $102,587,000 after buying an additional 623,730 shares during the period. BlackRock Inc. raised its stake in shares of Loxo Oncology by 20.6% in the second quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock worth $128,534,000 after buying an additional 273,291 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of Loxo Oncology by 50.2% in the second quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock worth $75,121,000 after buying an additional 312,988 shares during the period.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.